Literature DB >> 21466745

Identification of a blood-based biomarker panel for classification of Alzheimer's disease.

Christoph Laske1, Thomas Leyhe, Elke Stransky, Nadine Hoffmann, Andreas J Fallgatter, Janko Dietzsch.   

Abstract

An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable. Thus, there is a clear need to search for biomarkers in blood. In the present study, we have used multivariate data analysis [support vector machine (SVM)] to investigate whether a blood-based biomarker panel allows discrimination between AD patients and healthy controls at the individual level. We collected a total of 155 serum samples from individuals with early AD and age-matched healthy controls and measured serum levels of 24 markers involved in several biological pathways by ELISA. The dataset was randomly split into a training set for predictor discovery and classification training and a test set for class prediction of blinded samples (3:1 ratio) to evaluate the chosen predictors and parameters. After selection of a feature group of the three most discriminative parameters (cortisol, von Willebrand factor, oxidized LDL antibodies) in the training set, the application of SVM to the training/independent test dataset resulted in an 81.7%/87.1% correct classification for AD and control subjects. In conclusion, we identified a panel of three blood markers, which allowed SVM-based distinguishing of AD patients from healthy controls on a single-subject classification level with clinically relevant accuracy and validity. Blood-based biomarkers might have utility in AD diagnostics as screening tool before further classification with CSF biomarkers and imaging. Future studies should examine whether blood-based biomarkers may also be useful to differentiate AD patients from other dementias.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466745     DOI: 10.1017/S1461145711000459

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  28 in total

1.  Alzheimer disease: blood-based biomarkers in AD--a silver lining on the horizon.

Authors:  Christoph Laske
Journal:  Nat Rev Neurol       Date:  2012-08-14       Impact factor: 42.937

2.  A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual.

Authors:  Magda Bucholc; Xuemei Ding; Haiying Wang; David H Glass; Hui Wang; Girijesh Prasad; Liam P Maguire; Anthony J Bjourson; Paula L McClean; Stephen Todd; David P Finn; KongFatt Wong-Lin
Journal:  Expert Syst Appl       Date:  2019-04-10       Impact factor: 6.954

3.  Biomarkers of Alzheimer's disease among Mexican Americans.

Authors:  Sid E O'Bryant; Guanghua Xiao; Melissa Edwards; Michael Devous; Veer Bala Gupta; Ralph Martins; Fan Zhang; Robert Barber
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

4.  Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Authors:  Holly D Soares; William Z Potter; Eve Pickering; Max Kuhn; Frederick W Immermann; David M Shera; Mats Ferm; Robert A Dean; Adam J Simon; Frank Swenson; Judith A Siuciak; June Kaplow; Madhav Thambisetty; Panayiotis Zagouras; Walter J Koroshetz; Hong I Wan; John Q Trojanowski; Leslie M Shaw
Journal:  Arch Neurol       Date:  2012-10

5.  Blood-based protein biomarkers for diagnosis of Alzheimer disease.

Authors:  James D Doecke; Simon M Laws; Noel G Faux; William Wilson; Samantha C Burnham; Chiou-Peng Lam; Alinda Mondal; Justin Bedo; Ashley I Bush; Belinda Brown; Karl De Ruyck; Kathryn A Ellis; Christopher Fowler; Veer B Gupta; Richard Head; S Lance Macaulay; Kelly Pertile; Christopher C Rowe; Alan Rembach; Mark Rodrigues; Rebecca Rumble; Cassandra Szoeke; Kevin Taddei; Tania Taddei; Brett Trounson; David Ames; Colin L Masters; Ralph N Martins
Journal:  Arch Neurol       Date:  2012-10

6.  Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.

Authors:  Sid E O'Bryant; Guanghua Xiao; Fan Zhang; Melissa Edwards; Dwight C German; Xiangling Yin; Tori Como; Joan Reisch; Ryan M Huebinger; Neill Graff-Radford; Dennis Dickson; Robert Barber; James Hall; Padraig O'Suilleabhain; Paula Grammas
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.

Authors:  Liyong Wu; Pedro Rosa-Neto; Serge Gauthier
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

8.  Gene Expressions, Hippocampal Volume Loss, and MMSE Scores in Computation of Progression and Pharmacologic Therapy Effects for Alzheimer's Disease.

Authors:  Aydin Saribudak; Adarsha A Subick; Na Hyun Kim; Joshua A Rutta; M Umit Uyar
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2018-09-14       Impact factor: 3.710

9.  Plasma proteomics for the identification of Alzheimer disease.

Authors:  Liang-Hao Guo; Panagiotis Alexopoulos; Stefan Wagenpfeil; Alexander Kurz; Robert Perneczky
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

10.  Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics.

Authors:  Alcibiades E Villarreal; Sid E O'Bryant; Melissa Edwards; Shantal Grajales; Gabrielle B Britton
Journal:  Neurodegener Dis Manag       Date:  2016-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.